KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...
KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a leader in drug delivery platforms with a market capitalization of $31.77 million, has announced significant advancements in its DehydraTECH ...
BBC Good Food on MSN18h
Weight loss drugs – are they right for you?Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...
Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback